Cyrano Therapeutics is savoring a phase 2 victory.
Cyrano Therapeutics reported its Phase 2 Flavor study met the primary endpoint for treating persistent smell loss and plans a pivotal Phase 3 trial in the second half of the year.
Why it mattersPhase 2 success for persistent smell loss (Flavor study) signals investors to ready Phase 3 financing.